Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $8.00 at Piper Sandler

Aquestive Therapeutics (NASDAQ:AQST) had its price objective raised by Piper Sandler from $5.00 to $8.00 in a research note published on Friday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other research analysts also recently weighed in on the stock. JMP Securities raised their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a report on Thursday, October 9th. Oppenheimer raised their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Citigroup reiterated an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Lifesci Capital raised Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Trading Down 1.5%

NASDAQ AQST traded down $0.09 on Friday, reaching $6.04. The stock had a trading volume of 2,820,749 shares, compared to its average volume of 3,024,716. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $7.55. The business has a 50 day moving average price of $5.88 and a 200 day moving average price of $4.27. The company has a market capitalization of $736.88 million, a price-to-earnings ratio of -8.51 and a beta of 1.79.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $12.81 million during the quarter, compared to analyst estimates of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Cassie Jung sold 67,575 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $7.01, for a total transaction of $473,700.75. Following the transaction, the chief operating officer owned 240,771 shares of the company’s stock, valued at approximately $1,687,804.71. The trade was a 21.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Barber sold 91,343 shares of the stock in a transaction on Friday, September 26th. The shares were sold at an average price of $6.03, for a total transaction of $550,798.29. Following the completion of the sale, the chief executive officer directly owned 923,430 shares of the company’s stock, valued at approximately $5,568,282.90. This trade represents a 9.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 276,770 shares of company stock worth $1,692,203. Corporate insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds have recently made changes to their positions in AQST. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after buying an additional 2,649 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Aquestive Therapeutics by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock worth $106,000 after purchasing an additional 4,557 shares in the last quarter. Bank of Montreal Can increased its position in shares of Aquestive Therapeutics by 31.1% during the second quarter. Bank of Montreal Can now owns 20,052 shares of the company’s stock valued at $66,000 after purchasing an additional 4,752 shares during the period. Finally, Summit Wealth & Retirement Planning Inc. raised its stake in shares of Aquestive Therapeutics by 50.0% in the third quarter. Summit Wealth & Retirement Planning Inc. now owns 15,000 shares of the company’s stock valued at $84,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.